Pasithea Therapeutics (KTTA) Stock Price, News & Analysis

Company Overview

Pasithea Therapeutics Corp. is a biotechnology company focused on developing treatments for central nervous system disorders and other serious diseases. The company’s research has included novel pharmaceutical therapies as well as psychedelic- and ketamine-assisted treatment approaches for conditions such as depression and other mental health disorders.

Pasithea’s development portfolio has included PAS-004, an orally administered MEK1/2 inhibitor designed to affect the RAS/MAPK signaling pathway. The company has pursued potential applications for this type of therapy in oncology and other diseases involving abnormal cellular signaling, while continuing to evaluate opportunities in neuroscience.

Historically, Pasithea also operated or planned ketamine treatment clinics in the United States and the United Kingdom and conducted research involving psychedelic medicines. The company was founded in 2020, with neuroscientist and psychiatrist Dr. Tiago Reis Marques serving as a key member of its founding leadership.

Key Stats

• Today's Range: $0.40 to $0.44
• 50-Day Range: $0.41 to $0.60
• 52-Week Range: $0.28 to $2.06
• Volume: 9,078 shs
• Average Volume: 444,509 shs
• Market Capitalization: $14.30 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.00
• Consensus Rating: Hold

Pasithea Therapeutics Stock Analysis - MarketRank™

Pasithea Therapeutics scored higher than 74% of companies evaluated by MarketBeat, and ranked 185th out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

Pasithea Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

Pasithea Therapeutics has a consensus price target of $3.00, representing about 632.8% upside from its current price of $0.41.

Amount of Analyst Coverage

Pasithea Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Pasithea Therapeutics are expected to grow in the coming year, from ($0.76) to ($0.46) per share.

Price to Book Value per Share Ratio

Pasithea Therapeutics has a P/B Ratio of 0.17. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.49% of the float of Pasithea Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Pasithea Therapeutics has a short interest ratio ("days to cover") of 1.06, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Pasithea Therapeutics has recently decreased by 40.82%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pasithea Therapeutics does not currently pay a dividend.

Dividend Growth

Pasithea Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 4.0 / 5
• News Sentiment: 1.39

News Sentiment

Pasithea Therapeutics has a news sentiment score of 1.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Pasithea Therapeutics this week, compared to 2 articles on an average week.

Search Interest

3 people have searched for KTTA on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added Pasithea Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Pasithea Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.50% of the stock of Pasithea Therapeutics is held by insiders.

Percentage Held by Institutions

23.92% of the stock of Pasithea Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 10/15/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:KTTA
• CIK: 1841330
• Web: www.pasithea.com
• Phone: 702-514-4174
• Fax: N/A
• Employees: 5
• Year Founded: 2020

Price Target and Rating

• Average Price Target for Pasithea Therapeutics: $3.00
• High Price Target: $3.00
• Low Price Target: $3.00
• Potential Upside/Downside: +584.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.58)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$20.43 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -49.49%
• Return on Assets: -46.81%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 26.25
• Quick Ratio: 26.25

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.39 per share
• Price / Book: 0.18

Miscellaneous

• Outstanding Shares: 33,410,000
• Free Float: 32,913,000
• Market Cap: $14.63 million
• Optionable: Not Optionable
• Beta: 0.34